$RVPH
REVIVA PHARMACEUTICALS HOLDINGS, INC.

2023 Q2 Form 10-Q Financial Statement

#000143774923014582 Filed on May 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.079M $1.501M
YoY Change 206.37% -7.38%
% of Gross Profit
Research & Development $8.991M $5.235M
YoY Change 99.17% -10.21%
% of Gross Profit
Depreciation & Amortization $0.00
YoY Change
% of Gross Profit
Operating Expenses $12.07M $6.736M
YoY Change 118.69% -9.59%
Operating Profit -$12.07M -$6.736M
YoY Change 118.69% -9.59%
Interest Expense $12.76K $7.655K
YoY Change 66.13% -3428.26%
% of Operating Profit
Other Income/Expense, Net -$365.9K $136.0K
YoY Change -297.02% 53.18%
Pretax Income -$12.44M -$6.600M
YoY Change 133.16% -10.35%
Income Tax $6.436K $2.978K
% Of Pretax Income
Net Earnings -$12.40M -$6.600M
YoY Change 133.96% -10.39%
Net Earnings / Revenue
Basic Earnings Per Share -$0.55 -$0.30
Diluted Earnings Per Share -$0.55 -$0.30
COMMON SHARES
Basic Shares Outstanding 20.63M 20.45M
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.15M $11.26M
YoY Change -42.58% -51.94%
Cash & Equivalents $11.15M $11.26M
Short-Term Investments
Other Short-Term Assets $690.4K $1.646M
YoY Change -43.56% -10.89%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $11.84M $12.90M
YoY Change -42.64% -48.94%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $2.00 $3.00
YoY Change 100.0% 50.0%
TOTAL ASSETS
Total Short-Term Assets $11.84M $12.90M
Total Long-Term Assets $2.00 $3.00
Total Assets $11.84M $12.90M
YoY Change -42.64% -48.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.648M $2.861M
YoY Change 3.72% 100.62%
Accrued Expenses $6.338M $3.032M
YoY Change 229.37% 37.97%
Deferred Revenue
YoY Change
Short-Term Debt $222.5K $667.5K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.208M $6.560M
YoY Change 105.66% 81.05%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.012M $556.3K
YoY Change 857.89% 96.08%
Total Long-Term Liabilities $1.012M $556.3K
YoY Change 857.89% 96.08%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.208M $6.560M
Total Long-Term Liabilities $1.012M $556.3K
Total Liabilities $10.22M $7.117M
YoY Change 123.01% 82.14%
SHAREHOLDERS EQUITY
Retained Earnings -$110.2M -$97.80M
YoY Change 38.62% 31.81%
Common Stock $2.265K $2.045K
YoY Change 49.7% 35.16%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.621M $5.785M
YoY Change
Total Liabilities & Shareholders Equity $11.84M $12.90M
YoY Change -42.64% -48.94%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$12.40M -$6.600M
YoY Change 133.96% -10.39%
Depreciation, Depletion And Amortization $0.00
YoY Change
Cash From Operating Activities -$5.317M -$7.951M
YoY Change 32.89% 26.88%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.213M $687.1K
YoY Change 981461.43%
NET CHANGE
Cash From Operating Activities -5.317M -$7.951M
Cash From Investing Activities
Cash From Financing Activities 5.213M $687.1K
Net Change In Cash -104.0K -$7.264M
YoY Change -97.4% 15.92%
FREE CASH FLOW
Cash From Operating Activities -$5.317M -$7.951M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7450157 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1500554 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
7450157 usd
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20447371
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6599565 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2978 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6602543 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.30
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21833598
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001742927
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
0 usd
CY2023Q1 us-gaap Short Term Borrowings
ShortTermBorrowings
667500 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
6560237 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6039840 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2860578 usd
CY2023Q1 rvph Accrued Liabilities And Other Current Liabilities
AccruedLiabilitiesAndOtherCurrentLiabilities
3032159 usd
CY2023Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
556313 usd
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
567439 usd
CY2023Q1 us-gaap Liabilities
Liabilities
7116550 usd
CY2022Q4 us-gaap Liabilities
Liabilities
6607279 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20452121
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
2045 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
103485612 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-91171261 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
12316396 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18923675 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
6735553 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6735553 usd
CY2023Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
11126 usd
CY2022Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
89010 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
7655 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
-0 usd
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
147011 usd
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1735 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-14494 usd
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1967 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
135988 usd
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
88778 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7361379 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3629 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-7365008 usd
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18466586
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
12316396 usd
CY2023Q1 rvph Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
19593 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
51527 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6602543 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
5784973 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6602543 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-7365008 usd
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-11126 usd
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-89010 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1242152 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-110213 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
51527 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
39686 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-659693 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
674930 usd
CY2023Q1 us-gaap Cash
Cash
11300000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6600000 usd
CY2023Q1 rvph Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
512590 usd
CY2022Q1 rvph Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
362412 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7951397 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6266777 usd
CY2023Q1 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
667500 usd
CY2022Q1 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
0 usd
CY2023Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
19593 usd
CY2022Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
70 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
687093 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
70 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-7264304 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-6266707 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18519856 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
29687944 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11255552 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
23421237 usd
CY2023Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
2241 usd
CY2022Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
675 usd
CY2023Q1 rvph Working Capital
WorkingCapital
6300000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-97800000 usd
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15076630
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<span style="text-decoration: underline; ">Use of estimates</span>The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting periods covered by the financial statements and accompanying notes. Significant areas requiring the use of management estimates include, but are not limited to, depreciative and amortization useful lives, assumptions used to calculate the fair value of stock-based compensation, warrant liabilities, deferred tax assets, and related valuation allowances. Actual results could differ materially from such estimates under different assumptions or circumstances.
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<span style="text-decoration: underline; ">Concentration of credit risk and other risks and uncertainties</span>Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. Currently, the Company’s cash and cash equivalents are (and as of March 31, 2023 and December 31, 2022, all of the Company’s cash and cash equivalents were) held in demand deposit form at two financial institutions. Deposits in financial institutions may, from time to time, exceed federally insured limits. The Company has not experienced any losses on its deposits of cash.The Company is subject to all of the risks inherent in an early-stage company developing new pharmaceutical products. These risks include, but are not limited to, limited management resources, dependence upon medical acceptance of products in development, regulatory approvals, successful clinical trials, availability and willingness of patients to participate in human trials, and competition in the pharmaceutical industry. The Company’s operating results may be materially affected by the foregoing factors.
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18473128
CY2022Q3 us-gaap Share Price
SharePrice
2.20
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
51527 usd
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
39686 usd
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
422646 usd
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M12D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 usd
CY2023Q1 us-gaap Share Price
SharePrice
4.19

Files In Submission

Name View Source Status
rvph-20230331_cal.xml Edgar Link unprocessable
0001437749-23-014582-index-headers.html Edgar Link pending
0001437749-23-014582-index.html Edgar Link pending
0001437749-23-014582.txt Edgar Link pending
0001437749-23-014582-xbrl.zip Edgar Link pending
ex_512585.htm Edgar Link pending
ex_512586.htm Edgar Link pending
ex_512587.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rvph-20230331.xsd Edgar Link pending
rvph20230331_10q.htm Edgar Link pending
Show.js Edgar Link pending
rvph-20230331_def.xml Edgar Link unprocessable
rvph-20230331_lab.xml Edgar Link unprocessable
rvph-20230331_pre.xml Edgar Link unprocessable
rvph20230331_10q_htm.xml Edgar Link completed